Dynatronics (DYNT) Competitors $0.09 0.00 (-1.65%) As of 12:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock DYNT vs. QNRX, PTHL, CHEK, NDRA, VERO, TIVC, AEMD, GCTK, XAGE, and LGMKShould you be buying Dynatronics stock or one of its competitors? The main competitors of Dynatronics include Quoin Pharmaceuticals (QNRX), Pheton (PTHL), Check-Cap (CHEK), ENDRA Life Sciences (NDRA), Venus Concept (VERO), Tivic Health Systems (TIVC), Aethlon Medical (AEMD), GlucoTrack (GCTK), Longevity Health (XAGE), and LogicMark (LGMK). These companies are all part of the "medical equipment" industry. Dynatronics vs. Its Competitors Quoin Pharmaceuticals Pheton Check-Cap ENDRA Life Sciences Venus Concept Tivic Health Systems Aethlon Medical GlucoTrack Longevity Health LogicMark Quoin Pharmaceuticals (NASDAQ:QNRX) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment. Which has more volatility and risk, QNRX or DYNT? Quoin Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Dynatronics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Is QNRX or DYNT more profitable? Quoin Pharmaceuticals has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Dynatronics' return on equity of -41.81% beat Quoin Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Quoin PharmaceuticalsN/A -210.50% -99.41% Dynatronics -8.35%-41.81%-9.56% Do insiders and institutionals hold more shares of QNRX or DYNT? 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of Dynatronics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor QNRX or DYNT? In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Dynatronics. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Dynatronics. Quoin Pharmaceuticals' average media sentiment score of 0.94 beat Dynatronics' score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Quoin Pharmaceuticals Positive Dynatronics Neutral Which has better valuation & earnings, QNRX or DYNT? Dynatronics has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuoin PharmaceuticalsN/AN/A-$8.96M-$41.45-0.19Dynatronics$33.60M0.04-$2.70M-$0.78-0.11 SummaryQuoin Pharmaceuticals and Dynatronics tied by winning 6 of the 12 factors compared between the two stocks. Get Dynatronics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYNT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYNT vs. The Competition Export to ExcelMetricDynatronicsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18M$80.11M$5.69B$9.86BDividend YieldN/AN/A3.99%4.03%P/E Ratio-0.1111.5483.1126.58Price / Sales0.04100.48536.50112.00Price / CashN/A18.4137.7059.65Price / Book0.168.2610.576.59Net Income-$2.70M-$26.39M$3.27B$265.83M7 Day PerformanceN/A0.84%0.61%0.18%1 Month PerformanceN/A3.23%5.43%2.13%1 Year PerformanceN/A76.42%50.37%21.07% Dynatronics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNTDynatronicsN/A$0.09-1.6%N/A-43.1%$1.18M$33.60M-0.11200Gap DownQNRXQuoin Pharmaceuticals0.9688 of 5 stars$7.11-0.6%N/A-61.4%$4.20MN/A-0.174PTHLPhetonN/A$0.59-8.5%N/AN/A$3.87M$450K0.0011News CoverageGap DownCHEKCheck-Cap0.6676 of 5 stars$0.66-0.8%N/A-64.6%$3.84MN/A-0.2280Positive NewsNDRAENDRA Life Sciences2.8745 of 5 stars$4.64-3.7%$50.00+977.6%-71.1%$3.49MN/A-0.1420News CoverageVEROVenus Concept0.6384 of 5 stars$2.38+2.6%N/A-63.7%$3.38M$64.83M-0.05410TIVCTivic Health Systems0.7576 of 5 stars$3.04-8.2%N/A-45.3%$3.28M$780K0.0010Gap DownAEMDAethlon Medical2.5517 of 5 stars$1.14-3.0%$56.00+4,833.9%-41.1%$2.96M$570K-0.0910Gap DownGCTKGlucoTrack0.4851 of 5 stars$5.50-3.8%N/A-99.9%$2.64MN/A-0.105XAGELongevity HealthN/A$2.49+1.6%N/AN/A$2.50M$1.05M0.0014Positive NewsGap DownLGMKLogicMark0.1093 of 5 stars$0.00flatN/A-99.9%$2.25M$9.88M0.0020Gap Up Related Companies and Tools Related Companies Quoin Pharmaceuticals Competitors Pheton Competitors Check-Cap Competitors ENDRA Life Sciences Competitors Venus Concept Competitors Tivic Health Systems Competitors Aethlon Medical Competitors GlucoTrack Competitors Longevity Health Competitors LogicMark Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYNT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynatronics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynatronics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access